
We are a spin-off from the Ludwig-Maximilians-University Munich. Our mission is to support patient stratification in targeted cancer therapy, across novel targeted therapeutics (ADC, CAR-T, RLT, etc.), by providing functional biomarker solutions. Through the MAA (Molecular Affinity Analysis) platform, we support more precise patient selection, helping to optimize patient stratification and clinical trial designs and supporting the development of targeted cancer therapies. Our goal is to contribute to improved outcomes and quality of life for cancer patients of all ages and cancer types by delivering more accurate and actionable diagnostic insights.

Dr. Alexander Beck
Co-Founder & Chief Executive Officer

Dr. Andreas Beck
Co-Founder & Chief Financial Officer

Dr. Dominikus Huber
Chief Medical Officer
We invite you to connect with us to explore how our Molecular Affinity Analysis (MAA) platform can address your research and clinical objectives. Whether your focus is on enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how MAA technology can contribute to your success in drug development and precision oncology.